Robert Lorne Hopfner - 10 Jun 2022 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Role
Director
Signature
/s/ Axel Bolte, as attorney-in-fact for Robert Hopfner
Issuer symbol
INZY
Transactions as of
10 Jun 2022
Net transactions value
$0
Form type
4
Filing time
14 Jun 2022, 07:49:53 UTC
Previous filing
26 May 2022
Next filing
29 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INZY Stock Option (Right to Buy) Award $0 +9,367 $0.000000 9,367 10 Jun 2022 Common Stock 9,367 $4.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on June 10, 2022. The shares underlying the option are scheduled to vest as to 100% of the shares on June 10, 2023, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.